How to read a Drug Facts label

FDA's public label database held 47,102 documents for over-the-counter human drugs when it was last updated on Oct. 30, 2026, against 34,924 for prescription drugs, according to the openFDA drug label dataset⁷. Nearly every one of those OTC labels carries the same enclosed panel headed "Drug Facts," with the same headings in the same order.

That uniformity dates to a final rule FDA published on March 17, 1999², which took effect April 16, 1999. Products already approved under an application had until April 16, 2001, to comply. Low-volume products, those with annual sales under $25,000, got until April 16, 2002, and the rule set April 18, 2005, as the outer deadline for several other groups. FDA's own timeline lists 1999 as the year the Drug Facts label was created⁴.

Because the regulation fixes the order, a reader who learns it once can read any OTC box in seconds. This guide goes heading by heading through 21 CFR 201.66¹, the section that defines the panel, and uses a current generic ibuprofen 200 mg tablet label from the openFDA dataset as a worked example.

The headings, in the order the rule requires

Paragraph (c) of the rule lists the title and eight headings. The first seven headings are mandatory where they apply, and the last, a phone number for questions, is optional. They must appear "in the order listed," the regulation says¹.

Two placement rules make the top of the panel easy to scan. Active ingredients sit on the left with their purposes aligned on the right, and when a product has several active ingredients they are listed alphabetically, under paragraph (d)(6)¹. This is the line to compare when two boxes on a shelf carry different brand names, and it is also the line our guide to store-brand OTC medicines uses to match a store brand with a national one.

Inside the Warnings section

Warnings is the longest section on most panels, and its internal order is also fixed. Under paragraph (c)(5)¹, the subheadings run as follows:

• "For external use only," or rectal or vaginal use only, for products not meant to be swallowed
• Named warnings with bold labels where they apply, such as Reye's syndrome, allergy alert, flammability, choking, liver warning, stomach bleeding warning and sore throat warning
• "Do not use," for absolute contraindications
• "Ask a doctor before use if you have," for preexisting conditions and certain symptoms
• "Ask a doctor or pharmacist before use if you are," for drug-drug and drug-food interactions
• "When using this product," for side effects and things to avoid, such as alcohol or driving
• "Stop use and ask a doctor if," for signs of toxicity or reactions that call for stopping
• The pregnancy and breast-feeding warning, then "Keep out of reach of children" with the overdose statement

The regulation defines each one narrowly. "Do not use" covers situations in which consumers should not use the product "unless a prior diagnosis has been established by a doctor" or under any circumstances. "Ask a doctor before use" is reserved for situations in which consumers should not use the product until a doctor is consulted. Interactions get their own subheading, and it is the only one that names the pharmacist.

In the ibuprofen example, the interaction line flags people taking aspirin for heart attack or stroke, people under a doctor's care for a serious condition, and people "taking any other drug." The overdose statement prints the national Poison Help number. For approved-application products whose packaging has no toll-free complaint line, the "Stop use" subheading must also carry FDA's adverse event line, 1-800-FDA-1088, under paragraph (c)(5)(vii)¹.

Anyone weighing those warnings against their own health conditions or other medicines has a question for a pharmacist or doctor, which is the point of the wording. The label tells a reader when to ask. It does not answer the question for a specific person.

Format rules that make the panel readable

FDA's 1997 proposal described the goals as standardized headings, standardized graphics such as Helvetica type and bullet points, and minimum type sizes, according to the 1999 final rule's background section². The final rule did not require Helvetica, but paragraph (d)¹ sets these specifications:

Two smaller rules explain things readers notice. Graphics such as the bar code may not interrupt the panel, and hyphens may be used only to punctuate compound words. When a panel runs onto a second side of the box, the continuation is titled "Drug Facts (continued)" and an arrow or similar graphic points the way.

What sits outside the box

Some important details are printed elsewhere on the package. FDA's consumer page on the OTC label³, updated in September 2026, lists them: the statement of identity (name, purpose and strength of the active ingredient), net quantity, the expiration date where applicable, the lot or batch code, and the name and address of the manufacturer, packer or distributor. The lot code is what recall notices cite, and our guide to where the lot number and expiration date sit on a package shows where to find it. Our explainers on how expiration dates are set and how to check whether a medicine was recalled pick up from there.

The same page notes that dietary supplements are not covered. They are regulated as foods and carry a Supplement Facts panel instead, so a supplement sold next to an OTC drug follows a different template. FDA also cautions that "many OTC medicines may have similar brand names with different active ingredients," which is another reason the active ingredient line matters more than the front of the package.

Prescription medicines, the ones marked "Rx only", have no Drug Facts panel. They use the prescribing information format, plus a pharmacy label, as described in our guides to reading a prescription label and Medication Guides. Molecules sold both ways, such as famotidine and omeprazole, carry a Drug Facts panel on the OTC version and full prescribing information on the prescription version.

Changes on the way

Rules for what goes into each panel are also shifting. The CARES Act, signed March 27, 2020, created an administrative order process for adding, removing or changing the conditions in an OTC monograph, which FDA or an outside requestor can start, according to FDA's page on monograph reform⁵. The Drug Facts format in 21 CFR 201.66 stays in place, while the monograph conditions that fill it, which FDA says include labeling, can now change by order.

A second change concerns a new kind of product. Under FDA's final rule on drugs with an additional condition for nonprescription use⁶, effective May 27, 2025, some OTC drugs may require a consumer to complete an extra step, such as a questionnaire, before buying or using them. FDA says information on the label of such a product "will alert consumers." When GxRadar checked in November 2026, FDA's page said no such product had yet been approved.